JMP Securities Reiterates Market Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL)

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “market outperform” rating restated by investment analysts at JMP Securities in a note issued to investors on Tuesday,Benzinga reports. They presently have a $22.00 price target on the stock.

Several other equities research analysts have also recently commented on VIGL. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research report on Friday, November 8th. Guggenheim decreased their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Finally, Wedbush boosted their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Vigil Neuroscience currently has an average rating of “Moderate Buy” and an average price target of $16.60.

Vigil Neuroscience Stock Up 4.5 %

Shares of NASDAQ VIGL opened at $2.30 on Tuesday. The firm has a market cap of $94.02 million, a P/E ratio of -1.12 and a beta of 1.92. Vigil Neuroscience has a twelve month low of $2.08 and a twelve month high of $6.06. The company has a 50 day moving average of $3.44 and a 200 day moving average of $3.65.

Institutional Investors Weigh In On Vigil Neuroscience

A number of hedge funds have recently modified their holdings of VIGL. Acadian Asset Management LLC purchased a new position in Vigil Neuroscience during the second quarter valued at $26,000. Renaissance Technologies LLC lifted its position in shares of Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after buying an additional 11,536 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vigil Neuroscience during the 2nd quarter valued at approximately $87,000. Geode Capital Management LLC increased its holdings in Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after acquiring an additional 66,712 shares in the last quarter. Finally, Walleye Capital LLC raised its stake in Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after acquiring an additional 92,217 shares during the period. Institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.